TY  - JOUR
TT  - Opioid use in advanced stage cancer patients
AU  - Karataş, Fatih
PY  - 2018
DA  - June
DO  - 10.21601/ortadogutipdergisi.343002
JF  - Ortadoğu Tıp Dergisi
JO  - omj
PB  - MEDİTAGEM Ltd. Şti.
WT  - DergiPark
SN  - 2548-0251
SP  - 93
EP  - 97
VL  - 10
IS  - 2
KW  - Kanser ağrısı
KW  - opioid tedavisi
KW  - düşük doz opioid
KW  - yüksek doz opioid
N2  - Objective: Wewanted to evaluate the dose intensity and the rate of opioid use in patientshospitalized with a diagnosis of cancer at Medical Oncology Department.Cancer pain, opioid therapy, low-dose opioid, high-dose opioidPatients and Methods: Juneto December 2014, data were retropectively analiysed from 173 patients in 490advanced cancer patients who were admitted to our clinic and received opioidtreatment. Types of opioid use divided as weak (equal to ≤100 mg/day and strong (equal to >100 mg/daymorphine), and the opioid dose intensity were examined.Results: A total of 173patients, 114 (66.3%) were male and 58 (33.7%) were female, mean age of59.9±4.12 were found. 141 (81.5%) patients had metastases, 32 (18.5%) patientshad no metastases. According to type of cancer, 37 patients were classified(21.4%) lung, 34 (19.7%) of the stomach, 22 patients (12.7%), breast, and 17(9.8%), leukemia, lymphoma, 16 (9.2%), colon and 16 (9.2%) of the prostate, 11patients (6.4%), the rectum, and 10 (5.8%), pancreatic cancer, and 10 patients (5.8%)present in other cancers. There were no statistically differences found amongopioid side effects according to opioid dosage (P > 0.05).Conclusion: Regardlessof the type of cancer, high doses of opioid are required in at least one of thethree opioid-utilizing patients. Since high dose opioid use does not bring withit a higher risk of side effects, the opioid should be used in an effective andvery high dose of opioid when it is needed for palliation of pain in cancerpatients.
CR  - 1.	Foley KM. The treatment of cancer pain. New England Journal of Medicine. 1985;313(2):84-95.
2.	Greco MT, Roberto A, Corli O, Deandrea S, Bandieri E, Cavuto S, et al. Quality of cancer pain management: an update of a systematic review of undertreatment of patients with cancer. Journal of clinical oncology. 2014;32(36):4149-54.
3.	Schug SA, Zech D, Dörr U. Cancer pain management according to WHO analgesic guidelines. Journal of pain and symptom management. 1990;5(1):27-32.
4.	Von Roenn JH, Cleeland CS, Gonin R, Hatfield AK, Pandya KJ. Physician attitudes and practice in cancer pain management: a survey from the Eastern Cooperative Oncology Group. Annals of Internal medicine. 1993;119(2):121-6.
5.	Ferrell BR, Wisdom C, Wenzl C. Quality of life as an outcome variable in the management of cancer pain. Cancer. 1989;63(11):2321-7.
6.	Forsythe LP, Alfano CM, George SM, McTiernan A, Baumgartner KB, Bernstein L, et al. Pain in long-term breast cancer survivors: the role of body mass index, physical activity, and sedentary behavior. Breast cancer research and treatment. 2013;137(2):617-30.
7.	Vardy J, Agar M. Nonopioid drugs in the treatment of cancer pain. Journal of Clinical Oncology. 2014;32(16):1677-90.
8.	Cepeda MS, Farrar JT, Baumgarten M, Boston R, Carr DB, Strom BL. Side effects of opioids during short‐term administration: Effect of age, gender, and race. Clinical Pharmacology & Therapeutics. 2003;74(2):102-12.
9.	Ricardo Buenaventura M, Rajive Adlaka M, Nalini Sehgal M. Opioid complications and side effects. Pain physician. 2008;11:S105-S20.
10.	Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain physician. 2008;11(2 Suppl):S133-53.
11.	Lawlor PG, Bruera E. Side-effects of opioids in chronic pain treatment. Current Opinion in Anesthesiology. 1998;11(5):539-45.
12.	Payne R, Mathias SD, Pasta DJ, Wanke LA, Williams R, Mahmoud R. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. Journal of Clinical Oncology. 1998;16(4):1588-93.
13.	Jeal W, Benfield P. Transdermal fentanyl. Drugs. 1997;53(1):109-38.
14.	Colak S, Erdogan MO, Afacan MA, Kosargelir M, Aktas S, Tayfur İ, et al. Neuropsychiatric side effects due to a transdermal fentanyl patch: hallucinations. The American journal of emergency medicine. 2015;33(3):477. e1-. e2.
15.	University of Wisconsin- Madison, Pain and Policy Study Group website[online], http://www.painpolicy.wisc.edu/countryprofiles/euro, 05.10.2017. .
16.	Vieweg WVR, Lipps WFC, Fernandez A. Opioids and methadone equivalents for clinicians. Primary care companion to the Journal of clinical psychiatry. 2005;7(3):86.
17.	Gomes T, Mamdani MM, Dhalla IA, Paterson JM, Juurlink DN. Opioid dose and drug-related mortality in patients with nonmalignant pain. Archives of internal medicine. 2011;171(7):686-91.
18.	Mercadante S, Guccione C, Di Fatta S, Alaimo V, Prestia G, Bellingardo R, et al. Cancer pain management in an oncological ward in a comprehensive cancer center with an established palliative care unit. Supportive Care in Cancer. 2013;21(12):3287-92.
19.	Mantyh PW. Bone cancer pain: from mechanism to therapy. Current opinion in supportive and palliative care. 2014;8(2):83.
20.	Deandrea S, Corli O, Consonni D, Villani W, Greco MT, Apolone G. Prevalence of breakthrough cancer pain: a systematic review and a pooled analysis of published literature. Journal of pain and symptom management. 2014;47(1):57-76.
UR  - https://doi.org/10.21601/ortadogutipdergisi.343002
L1  - https://dergipark.org.tr/en/download/article-file/495531
ER  -